Mylan Scores PTAB Review Of Teva’s Copaxone Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva's three-times-a-week Copaxone has been key to its franchise protection; now that defense could quickly come under generic threat as well.